February 3, 2022 10:53 AM EST
R&D
News Briefing

Macro­Gen­ics ear­marks $580M for ADC tech; Do­mainex, non­prof­it team up on Parkin­son's pro­gram

Josh Sullivan

Synaf­fix and Macro­Gen­ics have signed a deal to code­vel­op and com­mer­cial­ize a clin­i­cal plat­form for an­ti­body-drug con­ju­gates to fight can­cer. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: CEO of Unit­ed­Health in­sur­ance unit shot and killed in New York in what po­lice call ‘a brazen, tar­get­ed ...

Blue­bird and Ver­tex's sick­le cell gene ther­a­pies to kick off new Med­ic­aid ac­cess mod­el

Lil­ly beats No­vo in bell­wether head-to-head weight loss study

As 23andMe strug­gles, an­oth­er ge­net­ic test­ing com­pa­ny bets on drug dis­cov­ery

Mod­er­na CEO de­fends pan­dem­ic prep ef­forts with crit­ics set to en­ter Trump’s ad­min­is­tra­tion

Trade group tells FDA that semaglu­tide is not too 'com­plex' for com­pound­ing

A service from the Financial Times